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ABSTRACT 18 
Dendritic cells (DC) are central to the initiation of immune responses and various 19 
approaches have been used to target vaccines to DC in order to improve immunogenicity. 20 
Cannulation of lymphatic vessels allows for the collection of DC that migrate from the skin. 21 
These migrating DC are involved in antigen uptake and presentation following vaccination. 22 
Human replication-deficient adenovirus (AdV) 5 is a promising vaccine vector for delivery 23 
of recombinant antigens. Although the mechanism of AdV attachment and penetration has 24 
been extensively studied in permissive cell lines, few studies have addressed the 25 
interaction of AdV with DC. In this study, we investigated the interaction of bovine skin-26 
migrating DC and replication deficient AdV-based vaccine vectors. We found that despite 27 
lack of expression of CAR and other known adenovirus receptors, AdV readily enters skin-28 
draining DC via actin-dependent endocytosis. Virus exit from endosomes was pH-29 
independent and neutralizing antibodies did not prevent virus entry but did prevent virus 30 
translocation to the nucleus. We also show that combining adenovirus with adjuvant 31 
increases the absolute number of intracellular virus particles per DC but not the number of 32 
DC containing intracellular virus. This results in increased trans-gene expression and 33 
antigen presentation. We propose that in the absence of CAR and other known receptors, 34 
AdV5-based vectors enter skin-migrating DC using actin-dependent endocytosis which 35 
occurs in skin-migrating DC and its relevance to vaccination strategies and vaccine vector 36 
targeting is discussed. 37 
  38 
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INTRODUCTION  39 
Vaccines based on replication incompetent adenovirus (AdV) vectors are safe and highly 40 
immunogenic, capable of inducing a full spectrum of adaptive humoral and cell-mediated 41 
immune responses, and of inducing protective immunity in a number of animal species 42 
including man (Dicks et al., 2015; Green et al., 2015; Taylor et al., 2015). 43 
Human adenovirus 5 (AdV5 and sometimes referred to as HAdV-C5), a species C 44 
adenovirus, is the most commonly studied adenovirus vector for both gene therapy and 45 
vaccination and so it is also the most studied in terms of cell entry, host responses and 46 
gene expression (Smith et al., 2010). Epithelial cell models have been used to describe 47 
the mechanism of AdV5 entry and trafficking to the nuclear membrane (Svensson & 48 
Persson, 1984; Wolfrum & Greber, 2013). It is generally accepted that the first step in 49 
AdV5 entry to its target cell is the binding of the virus’ fiber protein to CAR (Coxsackie B-50 
Adenovirus Receptor), followed by the binding of the RGD motif on the penton base to 51 
cellular integrins (avb3 and avb5). This promotes virus endocytosis into clathrin-coated 52 
vesicles and triggers the first step of the uncoating program (Burckhardt et al., 2011). 53 
Once inside the cell, the virus exits endosomal vesicles to the cytosol, where it utilizes 54 
microtubule motors to traffic to the nuclear membrane (Bremner et al., 2009) and deliver 55 
its DNA through the nuclear pore (Puntener et al., 2011).  56 
Although CAR has been shown to be the primary receptor for AdV5 entry in epithelial cells, 57 
CAR is not expressed on all cells that can be infected with AdV5. For example, infection of 58 
Kupffer cells is mediated by human blood coagulation factor X binding to AdV5 hexon 59 
(Alba et al., 2009; Kalyuzhniy et al., 2008; Waddington et al., 2008) and entry of AdV5 to 60 
human peripheral blood monocyte-derived dendritic cells involves CD209 (Adams et al., 61 
2009). 62 
 63 
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Since their identification (Steinman & Cohn, 1973), dendritic cells (DC) have become 64 
increasingly recognized for their crucial role as initiators and regulators of immune 65 
responses. Many studies of DC biology rely on the isolation of monocytes or macrophages 66 
from blood or tissues (such as spleen or bone marrow) (Rossi & Young, 2005; Steinman, 67 
1991), followed by maturation with interleukin 4 (IL-4) and granulocyte-macrophage 68 
colony-stimulating factor (GM-CSF), or the harvesting of tissues followed by isolation of 69 
resident DC. The cannulation of lymphatic vessels provides ex vivo DC derived from 70 
relevant anatomical sites such as the skin that drain sites of vaccination (Hemati et al., 71 
2009; Hope et al., 2006; Schwartz-Cornil et al., 2006). Due to the complexity of the 72 
surgical procedure to cannulate lymphatic vessels, this is most easily performed in large 73 
animals, such as cattle and sheep. We and others have described afferent lymph dendritic 74 
cells (ALDC) as being FSChigh MHCII+ DEC-205+ CD11c+ CD8a- (Cubillos-Zapata et al., 75 
2011; Gliddon et al., 2004; Hope et al., 2006). Within this population, subpopulations of DC 76 
expressing various levels of SIRPa (CD172a), CD11a, CD26 and CD13 have also been 77 
described (Brooke et al., 1998; Gliddon et al., 2004; Gliddon & Howard, 2002; Howard et 78 
al., 1997). Of these, the SIRPa+ DC population is targeted by various vaccine vectors and 79 
these cells are more efficient at antigen presentation compared to SIRPaneg/low ALDC 80 
(Guzman et al., 2012; Hope et al., 2012).  81 
 82 
In the current study, we describe the interaction between replication-deficient AdV5 with 83 
bovine ALDC that drain the skin. We show that macropinocytosis is the principal entry 84 
mechanism for AdV5 into ALDC and that the kinetics of virus internalization are much 85 
slower than previously described for epithelial cells. We also show that virus exit from 86 
endosomal compartments does not require an acidic microenvironment. Furthermore, 87 
neutralizing antibodies do not block internalization of AdV5 but prevent trans-gene 88 
expression. Finally, we demonstrate that emulsification of AdV5 in oil-in-water adjuvants 89 
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improve virus internalization into ALDC in vitro, increasing trans-gene expression and 90 
antigen presentation. Defining and manipulating entry pathways may enhance vaccine 91 
vector efficacy through improved antigen delivery and presentation. 92 
  93 
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RESULTS 94 
Bovine afferent lymph DC are transduced by adenovirus-based vectors despite the 95 
absence of known adenovirus receptors. 96 
We have previously shown that AdV5 injected subcutaneously or intramuscularly above 97 
the site of cannulation is internalized by migrating DC between 4 and 12 hrs post 98 
inoculation and that, in vitro, up to 40% of ALDC can be transduced by AdV5 using an moi 99 
of 100 (Cubillos-Zapata et al., 2011). To define the mechanism by which AdV5 transduces 100 
ALDC (defined as FSChigh MHCII+ DEC-205+ CD11c+ CD8a-, Fig. 1a), we initially assessed 101 
the expression of CAR on bovine cells including ALDC. CAR was detected by Western 102 
blotting in enriched membrane fractions from 293 and bovine lung (BL) cells but not 103 
membranes from bovine ALDC, (Fig. 1b). We then used the virus overlay binding assay 104 
(VOPBA) to confirm binding of AdV5 to bovine CAR. Under denaturing and non-denaturing 105 
conditions, AdV5 bound to enriched membrane fractions from 293 and BL cells, but not 106 
from ALDC (Fig. 1c and 1d). To confirm that AdV5 was binding specifically to CAR, a 107 
rabbit polyclonal antibody raised against CAR was used to block binding of AdV5 to CAR 108 
in a competition VOPBA assay (Fig. 1e). These results indicate that although AdV5 can 109 
use CAR for binding to BL cells, CAR is not expressed on bovine ALDC and, therefore 110 
AdV5 utilises an alternative entry strategy for ALDC that is CAR-independent.  111 
A number of different molecules have been implicated in AdV attachment to mononuclear 112 
phagocytic cells, including, MHC, CD80/86, CD209 and sialic acid (Chen & Lee, 2014). 113 
We used a combination of chymotrypsin, trypsin and papain to remove surface expression 114 
of known AdV receptors and brefeldin A to prevent their surface expression during 115 
transduction of ALDC. Following this treatment, the viability decreased to between 8 and 116 
12% as measured by trypan blue exclusion (data not shown). MHC I (Fig. 2a), MHC II (Fig. 117 
2b), CD80 (Fig. 2c), CD86 (Fig. 2d), and CD209, also known as DC-SIGN (Fig. 2e) were 118 
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completely removed by protease treatment and their reconstitution on the cell’s surface 119 
prevented throughout the course of the experiments. Removal of sialic acid with 120 
neurominidase (Fig. 2f) was also complete. In all cases, these treatments did not result in 121 
a decrease transduction efficiency of ALDC by AdV5-GFP (Fig.  2g-l). Blocking the RGD-122 
binding receptors with the antagonist Cyclo(Ala-Arg-Gly-Asp-3-Aminomethylbenzoyl 123 
decreased transduction efficiency of 293 cells but not ALDC (Fig. 2m and n). Finally, 124 
transduction of both 293 and ALDC was blocked by incubating in the presence of bovine 125 
hyperimmune serum against AdV5 (Fig. 2o and p). These results indicate that using the 126 
treatments indicated above, transduction of ALDC by AdV5 is not affected.  127 
Transduction kinetics of ALDC. 128 
To investigate transduction kinetics of ALDC by AdV5, we utilised biotinylated AdV5-GFP 129 
(moi = 100 vp/cell) to infect freshly isolated ALDC and 293 cells. After a 90 minute 130 
incubation at 4ºC or 37ºC, more than 60% of the biotinylated AdV5-GFP had attached to 131 
293 cells (Fig. 3a). In contrast, less than 5% of the biotinylated AdV5-GFP had attached to 132 
ALDC at either temperature. We also blocked attachment of AdV5 to 293 cells at both 133 
temperatures using anti-CAR antibodies and, as expected, we were able to block 95-98% 134 
of the AdV5-bio signal (data not shown). To confirm that biotinylation of the virus did not 135 
interfere with its ability to transduce cells and express encoded proteins, we also 136 
measured GFP expression in these cells by flow cytometry (Fig. 3b). A 90 minute 137 
incubation of 293 cells with biotinylated AdV5 at +4ºC or 37ºC, followed by washing off the 138 
excess inoculum and subsequent overnight incubation, was sufficient to transduce more 139 
than 80% of the cells. In contrast, <1% of ALDC expressed GFP following the same 140 
protocol. To determine the minimum time required for transduction of cells by AdV5, 293 141 
cells and ALDC were incubated with AdV5-GFP at 37ºC, the inoculum was washed off at 142 
one hour intervals, and the cells were incubated overnight. Transduction was measured by 143 
assessing the percentage of cells expressing GFP by flow cytometry. We determined that 144 
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1 hr incubation was sufficient for AdV5 to transduce and express GFP in 293 cells but that 145 
at least 5 hrs were required for ALDC to be significantly transduced by the virus (Fig. 3c). 146 
To determine the kinetics of transgene expression, ALDC cells were cultured with AdV5-147 
GFP (moi = 100) at 37ºC without washing, and GFP expression was measured at various 148 
time points by flow cytometry (Fig. 3d). GFP-positive 293 cells were evident at 4 hrs post 149 
transduction and by 8 hrs most cells were expressing the transgene. In contrast, at least a 150 
12 hr incubation period was required before a significant number of ALDC expressed GFP 151 
(Fig. 3d, p = 0.0071 %GFP expression in ALDC at 12 hrs compared to GFP expression at 152 
time 0). Expression of GFP in ALDC peaked after 24 hrs in culture. Interestingly, 153 
transgene expression in ALDC subsequently decreased and approached baseline levels 154 
by 48 hrs (Fig. 3d). These results indicate that the mechanism of AdV5 entry and trans-155 
gene expression in ALDC is significantly different to that in CAR-expressing 293 cells. 156 
ALDC actively uptake adenovirus. 157 
We then analysed the ability of a number of endocytosis inhibitors to block AdV5 entry and 158 
subsequent transduction. A fluorometric assay based on the capacity of trypan blue to 159 
quench extracellular but not intracellular fluorescein (Wan et al., 1993) was modified to 160 
determine the effect of various biochemical inhibitors on the capacity for ALDC to 161 
internalize fluorescein-labelled AdV5 (AdV5-Fluo). Incubation at 4ºC for 60 min followed by 162 
quenching with trypan blue blocked internalization of AdV5-Fluo and no fluorescence was 163 
detected in either cell type (Fig. 4b). All other treatments were carried out as described in 164 
Materials and Methods. In comparison with DMSO, treatment with the various inhibitors 165 
resulted in the following: treatment with filipin, which blocks caveolae and cholesterol-166 
dependent endocytosis, and chlorpromazine (CPZ), which inhibits clathrin-dependent 167 
endocytosis, reduced AdV5-Fluo uptake by 293 cells, as expected, but not by ALDC. In 168 
contrast, treatment with cytochalasin D (CCD), which blocks actin polymerization and 169 
amiloride, which blocks Na+ channels, both reduced the uptake of virus by ALDC (Fig. 4a 170 
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and b). Treatment with methyl-b-cyclodextrin (mb-CD), which blocks cholesterol-171 
dependent phagocytosis, did not have an effect on virus uptake in either cell type. 172 
Treatment with endocytosis inhibitors at the concentrations observed did not significantly 173 
increase the number of dead cells during the course of the assay (data not shown). This 174 
data indicates that actin polymerization and Na+/H+ exchange are required for AdV5 175 
uptake by ALDC.  176 
Transient association of AdV5 with early endosome markers. 177 
Following clathrin-mediated endocytosis of AdV5 in 293 cells, virus can be detected within 178 
clathrin-coated vesicles (Ashbourne Excoffon et al., 2003). These early endosomes are 179 
characterized by the presence of Rab5 and EEA1 (Christoforidis et al., 1999). To 180 
determine if entry of AdV5 into ALDC was associated with early endosomes, purified 181 
ALDC were cultured with AF568-labelled AdV5 for 1 to 6 hrs and analysed by confocal 182 
microscopy. AdV5 could not be detected on the surface of ALDC until 3 hrs after addition 183 
of virus when it was found to be associated with dendrites or cell membranes (Fig. 5a). An 184 
hour later a greater number of virions were associated with the dendrites/cell membrane 185 
and virions were also observed within the cytoplasm (Fig. 5b). By 5 hrs post infection, a 186 
proportion of virions were localized in proximity to the nucleus (Fig. 5c). We then stained 187 
AdV5-infected ALDC with EEA1-specific antibodies to determine localization of AdV5 with 188 
early endosomes. Although co-localization of AdV5-AF568 with EEA1 was observed at 4 189 
hrs post infection (Fig. 6a), co-localization events were rare, suggesting that virus exit from 190 
the phagosome/endosome occurs quickly after entry or that the majority of AdV are not 191 
associated with early endosomes. We then tracked the localization of AdV5-AF568 within 192 
ALDC using two different AF488-labelled tracers: dextran is used to track fluid-phase 193 
pinocytosis and albumin is known to enter cells using a mannose receptor-endocytosis 194 
pathway. We observed co-localization of AdV568 with dextran-AF488 but not with 195 
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albumin-AF488 (Fig. 6c-d), suggesting that AdV5 entry into ALDC is via fluid-phase 196 
macropinocytosis.  197 
Exit of AdV5 into the cytosol of ALDC is not pH-mediated. 198 
Following uptake, a key step in AdV5 infection is the exit of virus or virus aggregates from 199 
phagosomes/endosomes into the cytoplasm (Meier et al., 2005). To define the 200 
mechanisms associated with AdV5 exit in ALDC, cells were treated with inhibitors of the 201 
intracellular acidic microenvironment such as bafilomycin, NH4Cl or chloroquine, 60 min 202 
prior to the addition of AdV5-GFP. Cells were then cultured for 4 hrs and GFP expression 203 
measured by flow cytometry. None of the treatments significantly reduced the proportion of 204 
ALDC or 293 cells expressing GFP (Fig. 7A). To confirm the presence of acidic 205 
endosomes within ALDC, we utilized fluorescein-labelled dextran and fluorescein-labelled 206 
AdV5. The fluorescence of fluorescein is optimal at pH7.5 and rapidly decreases in acidic 207 
conditions. Under normal culture conditions, the fluorescence intensity (MFI) of 208 
fluorescein-labelled dextran within ALDC decreases after a 4 hr incubation (Fig. 7b), 209 
confirming the presence of dextran within endosomes and their subsequent acidification. 210 
In contrast, fluorescein-labelled AdV5 within ALDC did not show a decrease in 211 
fluorescence after a 4 hr incubation (Fig. 7b). As expected, normalization of intracellular 212 
pH with 10 mM NH4Cl, pH7.5, inhibited the reduction of fluorescence in dextran-loaded 213 
ALDC. To confirm these results, we measured the relative fluorescence of fluorescein at 214 
various pH and generated a standard curve (Fig. 7c). ALDC were incubated with 215 
fluorescein-labelled AdV5 or dextran and fluorescence was measured by real time 216 
fluorometry. Figure 7d shows that the fluorescence of dextran in ALDC decreases over 217 
time as the fluorescein becomes protonated, but the fluorescence of AdV5 remains the 218 
same suggesting that acidic endosomes are not involved in adenovirus uncoating in 219 
ALDC.  220 
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Neutralizing antibodies do not prevent virus entry into ALDC. 221 
An important hurdle to successful vaccination with viral vectors is the presence of 222 
neutralizing antibodies which can limit the efficacy of the vaccine. Most neutralizing 223 
antibodies are raised against the fibre protein of AdV and thus block virus attachment to its 224 
receptor (normally CAR). In light of our results, we sought to investigate the effect of 225 
neutralizing antibodies on AdV5 entry into ALDC. We incubated AdV5-568 with normal 226 
bovine sera, hyperimmune bovine sera to AdV5 or mouse monoclonal anti-hexon 227 
antibodies. Virus-Ab complexes were then added to cultures of ALDC and virus entry 228 
assessed by confocal microscopy, 4-6 hrs post infection. Interestingly, the mean number 229 
of intracellular AdV5 was significantly higher (p=0.0027) in the presence of bovine 230 
hyperimmune sera or mouse anti-hexon antibodies compared to normal bovine sera (S1a). 231 
However, even after 6 hrs in culture, virus complexed with antibody did not migrate to the 232 
nuclear membrane, but remained in the mid-cytoplasm (S1b) whereas AdV5, incubated 233 
with normal bovine sera, migrated and was located proximal to the nuclear membrane as 234 
expected (S1c). This data shows that the presence of neutralising antibodies does not 235 
prevent attachment of the virus to the cell but rather block a process downstream of virus 236 
penetration. 237 
Oil-in-water adjuvants increase virus uptake and enhance antigen expression. 238 
Various approaches have been proposed to improve targeting of AdV vectors to DC, 239 
including modification of the virus fibre protein to increase virus binding and penetration to 240 
DC. Previous observations by us and others (Cubillos-Zapata et al., 2011; Ganne et al., 241 
1994) indicate that the use of oil-in-water emulsions as adjuvants to deliver AdV5-based 242 
vaccines significantly increases the magnitude of immune responses to the trans-gene in 243 
vivo. To identify the effect of adjuvanted vector on ALDC, AF568-labelled AdV5-GFP was 244 
prepared in an oil-in-water emulsion, or combined with the adjuvant without mixing, and 245 
incubated ALDC with the preparations. ALDC incubated with emulsified virus contained a 246 
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significantly greater number of intracellular virions compared to cells incubated with virus 247 
in adjuvant without mixing or in PBS (p = 0.0248, Figures 8a, b and c). The mean 248 
fluorescence intensity of GFP was greater (Fig. 8d) and expression was more sustained 249 
(Fig. 8e) in ALDC incubated with emulsified virus than in cells incubated with the virus in 250 
adjuvant without mixing or in PBS. However, the percentage of cells expressing the trans-251 
gene did not change (Fig. 8e). To confirm the effect of adjuvanted vector on antigen 252 
presentation, AdV5 expressing mycobacterial antigen 85A (Ag85A, (Cubillos-Zapata et al., 253 
2011)) in adjuvant was prepared with or without mixing and incubated with ALDC. These 254 
ALDC were then cultured with CD4+ T cells obtained from MHC-matched, BCG-vaccinated 255 
cattle. Ag85A-specific responses were significantly higher when AdV5-Ag85A was mixed 256 
with adjuvant compared to AdV5-Ag85A without mixing or without adjuvant (p = 0.0076). 257 
The number of IFN-g producing cells was minimal when T cells were cultured with ALDC 258 
exposed to AdV5-GFP with or without adjuvant, or to adjuvant alone (Fig. 8f). This data 259 
shows that in the absence of genetic modification of the virus fibre, increased transduction 260 
efficiencies can be achieved by the use of water-in-oil adjuvants. 261 
DISCUSSION 262 
We have previously shown that in contrast to monocyte-derived DC, ALDC can be readily 263 
transduced by replication-deficient AdV5 (Cubillos-Zapata et al., 2011), achieving up to 264 
50% transduction of ALDC in vitro and up to 12% in vivo. ALDC can be separated into two 265 
main subpopulations, CD172α+ and CD172α-; only the former can be transduced by AdV5 266 
vectors both in vitro and in vivo (Cubillos-Zapata et al., 2011). In the current study, we 267 
aimed to characterize the mechanism of AdV5 uptake by ALDC further.  268 
Since its discovery as a primary receptor for AdV5 (Bergelson et al., 1997), it has been 269 
widely accepted that CAR is involved in AdV5 attachment to target cells. However, a 270 
number of other cell surface molecules, such as CD40, MHC II, CD46 and Fc receptors, 271 
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have  been identified which appear to play an important role in AdV5 attachment (reviewed 272 
in (Zhang & Bergelson, 2005)). We could not prevent the transduction of ALDC by AdV5 273 
following proteolytic cleavage of surface proteins or by using RGD-blocking peptides. 274 
Although there is evidence that DC-SIGN is involved in attachment of AdV5 to human 275 
monocyte-derived DC (Adams et al., 2009), we could not replicate these results using 276 
bovine ALDC. This may be due to differences between the interaction of AdV5 between 277 
human and bovine DC or to differences between monocyte-derived DC and ALDC. Apart 278 
from an antibody against CD64 (FcγR), antibodies against bovine FcγR are not available, 279 
so it is possible for these receptors to be involved in AdV5 entry into bovine ALDC. 280 
VOPBA has been used to identify the binding of dengue virus (Jindadamrongwech & 281 
Smith, 2004), pseudorabies virus (Karger & Mettenleiter, 1996) and respiratory syncytial 282 
virus (RSV) (Tayyari et al., 2011) to cell receptors. We used this assay under denaturing 283 
and non-denaturing conditions to determine if a protein receptor for AdV5 on membrane-284 
enriched fractions from ALDC could be identified. Although binding of virus to a protein 285 
present in enriched membrane fractions from 293 and BL cells could be detected, we 286 
could not identify binding of AdV5 to membrane proteins derived from ALDC (Figure 1). It 287 
is possible that our inability of identify an AdV5 receptor on ALDC is due to the stringency 288 
of the assay’s conditions or the sensitivity of our assays. New technologies developed to 289 
identify protein-protein interaction, such as FRET or high affinity co-immunoprecipitation 290 
followed by highly sensitive mass spectrometry may help identify receptors involved in 291 
AdV attachment in the future.  292 
Using biotinylated AdV5 we showed that the virus does not bind to the surface of ALDC as 293 
it does to the surface of 293 cells suggesting that internalization of AdV5 by bovine ALDC 294 
is mediated by CAR-independent macropinocytosis and similar pathways have been 295 
described for internalization other viruses such as influenza (de Vries et al., 2011) and 296 
vaccinia (Sandgren et al., 2010) by DC. Alternatively, it is possible for AdV5 to use low-297 
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affinity receptors present on the surface of ALDC as observed in other systems, such as 298 
CD46 (Sirena et al., 2004), αMβ2 and αLβ2 (Huang et al., 1996) integrins. It is possible 299 
that labelling the virus with sulfo-NHS conjugates (biotin, AF569, fluorescein) changes the 300 
way the virus enters the cells. We have tried to address this possibility by using non-301 
labelled virus as control and GFP as readout of transduction when at all possible. 302 
Professional phagocytic cells such as DC have the capacity to take up small and large 303 
particles using a variety of mechanisms such as macro- and micropinocytosis (Platt et al., 304 
2010; Savina & Amigorena, 2007). Using biochemical inhibitors of endocytosis, we found 305 
that cytochalasin D (CCD) was able to block AdV5 uptake indicating that AdV5 306 
internalization by ALDC is an actin-mediated process (Cooper, 1987), and that skin-307 
migrating DC utilize their capacity as professional phagocytic cells to survey peripheral 308 
sites acquiring foreign antigens such as vaccine vectors, and processing these antigens 309 
prior to and on arrival to local draining lymph nodes. Interestingly, dynasore had no effect 310 
on endocytosis of AdV5 indicating that this process is clathrin-independent (Chen et al., 311 
2009) and therefore does not require the binding of RGD to cellular integrins. This 312 
suggestion is supported by the finding that RGD blocking peptides did not inhibit AdV5 313 
internalization by bovine ALDC (Figure 2).  314 
We then looked at events following virus internalization, and using confocal microscopy we 315 
observed occasional co-localization of AdV5 particles with the early endosome marker 316 
EEA1, but not with the late endosome marker LAMP1 (data not shown), supporting 317 
previous evidence of AdV5 exit from early endosomes to the cytosol (Svensson & 318 
Persson, 1984). Although it has been previously proposed that AdV5 exits early 319 
endosomal compartments following intra-endosome acidification (Greber et al., 1993) and 320 
reviewed in (Smith et al., 2010), we could not block virus transduction of ALDC using a 321 
number of lysosomotropic agents. Additionally, the fluorescence intensity of AdV5-322 
fluorescein remained constant in ALDC over time whereas the fluorescence intensity of 323 
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fluorescein-labelled dextran declined as fluorescein became protonated (Figure 7b and d). 324 
Our data indicates that acidification of endosomes is not required for transduction of ALDC 325 
by AdV5 and this has been shown to be the case  in other systems (Otero & Carrasco, 326 
1987; Rodriguez & Everitt, 1996; Svensson & Persson, 1984), and although Suomalainen 327 
et al. found in epithelial cells that virus penetration is independent of low endosomal pH, it 328 
could still be inhibited by ammonium chloride; so it is possible that AdV5 exit to the cytosol 329 
requires acidification of endosomes in some cells but not others. This raises the question 330 
of how AdV5 exits endosomal compartments in ALDC. It has been proposed that viral 331 
(Suomalainen et al., 2013) or cellular proteases degrade early endosomes (Wiethoff et al., 332 
2005) or perhaps a yet unknown mechanism is involved in this process and requires 333 
further investigation. 334 
The presence of naturally-acquired neutralizing antibodies against AdV5 is one of the 335 
major obstacles in the deployment of effective recombinant AdV5 vaccine vectors (Ahi et 336 
al., 2011). Antibodies bound to neutralizing epitopes on the virus surface normally prevent 337 
virus binding to the cell’s receptors (Roy et al., 2005; Sumida et al., 2005). However, we 338 
observed that AdV hyperimmune bovine sera enhanced the uptake of AdV5 by ALDC, 339 
perhaps through the use of Fc receptors while blocking trans-gene expression. We could 340 
not test the effect of blocking Fc receptors due to the lack of available reagents to use in 341 
bovine cells. In the presence of AdV5-specific antibody, the AF568-labelled virions were 342 
not translocated to the nuclear membrane, but remained in the cytoplasm and the signal 343 
was eventually lost (data not shown). A similar phenomenon has been described 344 
previously in HeLa cells (Smith et al., 2008), in which TRIM21 binds to antibody-AdV5 345 
complexes and targets the complexes for proteasomal degradation (Mallery et al., 2010). 346 
The role of TRIM21 in AdV5 degradation remains to be investigated in DC. 347 
Various approaches have been proposed to improve targeting of AdV vectors to DC, 348 
including modification of the virus fibre protein to increase virus binding and penetration to 349 
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DC. In light of our current results and previous studies that have shown that AdV5 350 
emulsified in an oil-in-water adjuvant and injected over the site of cannulation provides 351 
longer trans-gene expression and improved immunogenicity compared to non-adjuvanted 352 
virus (Cubillos-Zapata et al., 2011), we sought to understand the mechanism of improved 353 
immunogenicity in the absence of clear virus fibre-receptor interactions. Cells transduced 354 
with adjuvanted virus contained more intracellular virions and trans-gene expression was 355 
stronger and longer-lasting than in cells transduced with virus in the presence of adjuvant 356 
but without emulsification, or in PBS. In presentation assays, antigen-specific IFN-g T cell 357 
responses were higher when adjuvanted virus was used. This suggests that the oil-in-358 
water emulsion provides a biological medium which is used by the DC to take up larger 359 
amounts of solute, in this case AdV5. This in turn translates into greater numbers of 360 
intracellular virions that have the capacity to translocate to the nucleus more effectively 361 
and for longer periods of time, or that the virions may be protected from intracellular 362 
degradation for a longer period of time when taken up in an adjuvant emulsion. This 363 
results in stronger trans-gene expression and thus antigen presentation. In addition, the 364 
adjuvant emulsion may activate TLRs which provide signals for the DC to be more 365 
effective at activating T cells. However, our controls suggest that this may not be the case 366 
since in vitro responses to AdV5-Ag85 in PBS are not significantly higher than responses 367 
to AdV5-Ag85 in adjuvant but without mixing (Figure 8f). Further studies are required to 368 
understand the relationship between biochemical adjuvants and DC. Ultimately, genetic 369 
modification of fibre protein will only be useful if a clear cellular receptor is identified in the 370 
target cell, therefore alternative approaches, such as oil-in-water emulsions, may be the 371 
most appropriate to improve AdV-based gene delivery. 372 
 373 
In conclusion, here we describe the interaction of a replication-deficient AdV vector with 374 
skin-migrating bovine DC, which are collected by cannulation of lymphatic vessels and are 375 
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not subject to culture in laboratory conditions. We present evidence of the phagocytic 376 
action of these DC. Upon encountering virus, ALDC actively phagocytose the virus 377 
particles, perhaps using an unknown low-affinity receptor, and which takes between 3 and 378 
4 hrs before virus particles can be observed intracellularly. Following entry, the virus 379 
quickly exits endosomal compartments via an unknown mechanism or is never associated 380 
with acidic endosomes, travelling to the nuclear membrane and so initiating trans-gene 381 
transcription and translation. Neutralizing antibodies do not only prevent virus entry into 382 
DC but enhance it whilst inhibiting translocation to the nucleus. Our data will be useful in 383 
understanding DC-vaccine interactions and will help further development and improvement 384 
of viral vectors. Defining and manipulating entry pathways may enhance vaccine vector 385 
efficacy through improved antigen presentation. 386 
METHODS 387 
Pseudoafferent lymphatic cannulation 388 
MHC-defined (Ellis et al., 1996; Ellis et al., 1998), conventionally reared, 6 month-old 389 
Friesian Holstein calves (Bos taurus) from The Pirbright Institute (Pirbright) herd were 390 
used for these studies. Cannulations were performed essentially as described previously 391 
(Hope et al., 2006). Lymph was collected into sterile plastic bottles containing heparin (10 392 
U/ml), penicillin (100 U/ml) and streptomycin (100 µg/ml). The lymph collected was either 393 
used fresh or was centrifuged (300 x g, 8 min), resuspended in heat-inactivated foetal calf 394 
serum (FCS, Autogen Bioclear) containing 10% DMSO and the cells stored in liquid 395 
nitrogen prior to use. Mononuclear cells were isolated from afferent lymph by density 396 
gradient centrifugation over Histopaque 1083 (Sigma). Mycobacterium bovis Ag85A-397 
specific T cells were obtained from MHC-defined cattle vaccinated subcutaneously with 398 
106 CFU of BCG Pasteur. All T cells used were collected 3 weeks post vaccination at the 399 
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peak of the response. All animal experiments were approved by the Pirbright’s ethics 400 
committee and carried out according to the UK Animal (Scientific Procedures) Act 1986. 401 
Cell lines and primary cells. 402 
293 and HeLa cells were obtained and maintained by the Microbiological Services 403 
Department (Pirbright) in tissue culture media (TCM) in the absence of antibiotics. CHO 404 
cells expressing human recombinant CAR (CHO-CAR) were provided by Dr M. 405 
Cottingham, Jenner Institute, University of Oxford, UK. Bovine ALDC (FSChigh MHCII+ 406 
DEC-205+ CD11c+ CD8a-) were separated from other lymph-migrating cells using a 407 
FACSAria II (Becton Dickinson) and purities were confirmed by flow cytometry using 408 
FACSDiva v6 (Becton Dickinson). Peripheral blood CD14+ monocytes, CD4+ and CD8+ T 409 
cells were magnetically separated using anti-human CD14 (Miltenyi Biotech), CC30 and 410 
CC63 mAbs (Guzman et al., 2008) respectively and MACS technology (Miltenyi Biotech, 411 
Germany) following the manufacturer’s instructions. Typically, the purity of the resulting 412 
dendritic and T-cell subsets was over 97% as determined by flow cytometry as described 413 
above. 414 
Bovine lung (BL) cells were isolated from Holstein cattle at the time of slaughter and were 415 
provided by Pirbright’s Microbiological Services Department (Chanter et al., 1986). 416 
Monoclonal antibodies and flow cytometry 417 
Fluorochrome-labelled mouse anti-bovine monoclonal antibodies (mAb) used in this study 418 
have been described in detail previously (Brooke et al., 1998; Howard et al., 1991; Howard 419 
& Naessens, 1993; Howard et al., 1997; Sallusto et al., 1995). These were CC98-APC 420 
(anti-DEC-205), CC14-PE (anti-CD1b), CC149-PerCP/Cy5.5 (anti-SIRPa), IL-A16-421 
AlexaFluor 680/PE (anti-CD11c), IL-A21-PE (anti-MHCII), ILA-88-FITC (anti-MHC I), IL-422 
A156-PE (anti-CD40), N32/52-3 –PE (anti-CD80) IL-A159-PE (anti-CD86), CC30-423 
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APC/Cy5.5 (anti-CD4), CC63-APC/Cy7 (anti-CD8), IL-A111-AlexaFluor 610/PE (anti-424 
CD25), CC302-PE (anti-IFN-g). Isotype- and concentration-matched anti-turkey 425 
rhinotracheitis virus mAbs were used as controls (Hope et al., 2006; Whelan et al., 2003). 426 
Dead cells were excluded using the 405 nm excitable dye Live/Dead Aqua or propidium 427 
iodide (Invitrogen) following the manufacturer’s instructions. The cells were acquired using 428 
an LSRFortessa (Becton Dickinson) and staining was analysed using FCS Express v4 429 
(DeNovo Software). Afferent lymph DC were distinguished from other cells on the basis of 430 
their high Forward Scatter (FSC), expression of MHC II, CD11c and high intensity 431 
expression of DEC-205 and lack of CD8α (Gliddon et al., 2004; Hope et al., 2006). Only 432 
live, single events were used for analysis. 433 
Viruses 434 
E1 and E3-deleted recombinant human AdV5 expressing green fluorescent protein (GFP) 435 
or mycobacterial antigen 85A (Ag85A) were generated by the Jenner Institute Viral Vector 436 
Core Facility, University of Oxford, UK, as described previously (Cubillos-Zapata et al., 437 
2011). 438 
For some assays, aliquots of 1x1011 vp AdV5 were labelled with NHS-AlexaFluor568, 439 
NHS-biotin or NHS-fluorescein (Invitrogen) following the manufacturer’s instructions and 440 
labelled virus was dialyzed twice against PBS. The virus was then titrated in 293 cells and 441 
GFP expression measured by flow cytometry. In some cases the titer was found to be 1 442 
log lower after labelling and the infectious doses were adjusted as required. 443 
Generation of bovine hyperimmune sera to AdV5 444 
Three six month old Holstein-Friesian calves were inoculated intramuscularly with 1x 109 445 
vp of purified AdV5 three times at six week intervals. The hyperimmune sera used was 446 
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collected 6 weeks after the last immunization, pooled, and tested in a virus neutralization 447 
assay (Sumida et al., 2005). 448 
Infection of afferent lymph cells 449 
Migrating cells from the afferent lymph were cultured (IMDM containing 10% FCS and 10-5 450 
M 2-b-mercaptoethanol (Sigma-Aldrich, Poole, UK) with the recombinant viruses using 451 
optimal multiplicities of infection, as described previously (Cubillos-Zapata et al., 2011). In 452 
some assays, transferrin-AF568 (Sigma) and dextran-fluorescein (Invitrogen) were used 453 
as tracing markers. In neutralization assays, AdV5 was incubated with 1 µg of anti-hexon 454 
antibody raised in goats (Millipore) or with bovine pre-immune or hyperimmune sera raised 455 
against human AdV5 generated by immunizing calves with 1x109 vp of AdV5 as described 456 
above.   457 
Detection of known adenovirus receptors and removal from cell surface 458 
To analyse the expression of known adenovirus receptors on ALDC and bovine lung cells 459 
the following antibodies were used in flow cytometry: N-17 (goat anti-CAR, Santa Cruz 460 
Biotechnology), N32/52-3 (anti-CD80), ILA-159 (anti-CD86), IL-A88 (anti-MHC class I), IL-461 
A21 (anti-MHC class II), T320.11 (anti-heparin/heparin sulphate, Merck), 2-2B (anti-sialic 462 
acid, Merck), CC30 (anti-CD4), CC63 (anti-CD8), 344519 (anti-CD46, R&D Systems), 463 
CCG24 (anti-FcgRII), KD1 (anti-FcgRIII, Abcam), C-20 (anti-DC-SIGN, Santa Cruz 464 
Biotechnology), LM609 (anti-avb3, Chemicon), mAb 2000 (anti-avb1, Chemicon), 10D5 465 
(anti-avb6, Millipore). All antibodies were obtained from Pirbright except where noted.  466 
Antibodies were added to cells (1 µg/106 cells) and incubated at 4ºC for 60 min. After 3 467 
washes with PBS the cells were stained with AF647-labelled goat, rabbit or mouse-specific 468 
secondary antibodies (Serotec) and the cells analysed by flow cytometry as described 469 
above. 470 
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Digestion of cell surface proteins was achieved using a mixture of proteolytic enzymes 471 
(Wald et al., 2001) consisting of 2U of trypsin, 1U of papain, 2U of chymotrypsin (Merck). 472 
106 cells were treated with the enzyme mix in a volume of 100 µl for 30 minutes at 37ºC; 473 
the cells were then washed twice in cold PBS and resuspended in culture media 474 
containing a final concentration of 5 µg/ml of brefeldin A (Sigma). 475 
Virus attachment assay by ELISA 476 
BL cells, ALDC, CD14+ monocytes or 293 cells were cultured on 96-well plates. Antibodies 477 
against known AdV5 receptors were added to the cells at 1 µg/106 cells; in some cases the 478 
following chemical agents known to block AdV5 entry were also added: 10 U of sodium 479 
heparin (Sigma), 1 U of trypsin (Sigma), or 10 mM RGD antagonist Cyclo(Ala-Arg-Gly-480 
Asp-3-Aminomethylbenzoyl (Sigma). After 1 hr incubation at 37°C the cells were washed 481 
in cold PBS, biotinylated AdV5 (moi=100 vp/cell) was added for 90 minutes on ice or at 482 
37ºC. The cells were then washed three times with ice-cold PBS and fixed with 3% 483 
paraformaldehyde (PF). After blocking with 1% bovine serum albumin (BSA) in PBS, 484 
streptavidin-HRP (Sigma, 1:500) was added and the plates incubated for 60 min at room 485 
temperature. The plates were washed with PBS-Tween and the plates developed with 486 
TMB Turbo (Pierce). Reactions were stopped with 1 M H2SO4 and optical densities were 487 
measured using a FluorostarOptima (BMG Labtech, Germany). 488 
Virus overlay protein binding assay (VOPBA) and Western blot. 489 
VOPBA was carried out essentially as described by (Cao et al., 1998) with a few 490 
modifications. Subcellular fractions from 1x106 293, BL and ALDC were enriched using the 491 
ProteoExtract subcellular fractionation kit (Merk Millipore) following the manufacturer’s 492 
instructions. Total cell protein and membrane fractions were separated by polyacrylamide 493 
gel electrophoresis (PAGE) on 4-10% denaturing and non-denaturing TGX stain-free gels 494 
(Bio-Rad) and transferred onto Immun-Blot PVDF membranes (Bio-Rad). The membranes 495 
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were blocked with 5% (w/v) dry milk-PBS overnight, rinsed with PBS and probed with 496 
AdV5 (1x108 vp in 10 ml of milk-PBS) for 90 minutes. The membranes were then washed 497 
three times with PBS and incubated with 10 µg of biotinylated goat anti-AdV5 (Serotec) in 498 
10 ml of milk-PBS for 60 minutes. The membranes were washed three times and 499 
incubated with 10 µg of streptavidin-conjugated horse radish peroxidase (HRP, Dako) in 500 
10 ml of milk-PBS for 60 minutes. After extensive washing, the membranes were 501 
developed with Immun-Star WesternC substrate (Bio-Rad) and visualized using a 502 
ChemiDocMP digital imager (Bio-Rad). For competition VOPBA and before the addition of 503 
AdV5, 10 µg of rabbit anti-CAR pAb (Abcam) was added to the membranes and incubated 504 
for 90 min at room temperature. After washing three times with PBS, the membranes were 505 
probed with AdV5 and the assay carried out as described above.  506 
For detection of CAR by Western blot, membrane fractions separated by PAGE were 507 
transferred onto PVDF membranes, blocked with milk-PBS and probed with 10 µg of rabbit 508 
anti-CAR pAb or 1 µg of anti-b actin mouse mAb (Abcam) in 10 ml of milk-PBS. After 509 
washing with PBS containing 1% Tween 20 (PBS-T), the membranes were incubated with 510 
1 µg of anti-goat or anti-mouse antibody conjugated to HRP (Dako) in 10 ml of milk-PBS 511 
for 60 minutes. After extensive washing with PBS-T, the membranes were developed as 512 
described above.  513 
Biochemical inhibitors. 514 
The following inhibitors and final concentrations were used to block endocytosis: 515 
cytochalasin D (CCD, 1 µM, actin-dependent (Sakr et al., 2001)); filipin (5 µg/ml caveolae-516 
dependent (Rothberg et al., 1992)); chlorpromazine (CPZ, 10 µg/ml, prevents clathrin-517 
coated pit formation (Wang et al., 1993)); methyl-b-cyclodextrin (mb-CD, 10 mM, 518 
cholesterol-dependent (Vieth et al., 2010)); amiloride (1 mM, Na+ blocker (West et al., 519 
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1989), and therefore blocks macropinocytosis (Sallusto et al., 1995)); ciliobrevin (10 µM, 520 
inhibitor of motor cytoplasmatic dynein (Firestone et al., 2012); dynasore (8 mM, inhibitor 521 
of dynamin and clathrin-dependent endocytosis (Macia et al., 2006)).  522 
The following lysosomotropic agents were used to block acidification of endosomal 523 
compartments: bafilomycin (1 µM, inhibitor of vacuolar-type H+-ATPase (Yoshimori et al., 524 
1991); NH4Cl (a weak base (Sonawane et al., 2002) and diluted in PBS); chloroquine (10 525 
µM, inhibits endosomal maturation (Mellman et al., 1986)). 526 
All inhibitors were diluted in dimethyl sulfoxide (DMSO), except where noted. DMSO was 527 
used as diluent control and PBS was used as a negative control. All chemicals were 528 
obtained from Sigma-Aldrich (Poole, UK). Cells (1x106 final) were plated in triplicate in 529 
culture media in 96 U-bottomed plates, the biochemical inhibitors added to the final 530 
concentrations described above in a final volume of 100 µl and mixed thoroughly. After 1hr 531 
incubation at 37ºC, virus internalization assays were performed as described below. 532 
Virus internalization assay. 533 
To differentiate between attachment and entry, a fluorometry phagocytosis assay (Wan et 534 
al., 1993) based on the capacity of trypan blue to quench extracellular fluorescein was 535 
modified. AdV5 was labelled with NHS-fluorescein (Pierce) following the manufacturer’s 536 
instructions. ALDC or 293 cells were cultured in 96-well plates with the labelled virus 537 
(moi=100 vp/cell) for 6 hrs or 60 min respectively at 37ºC or at 4ºC in the presence of the 538 
biochemical inhibitors described above. All inhibitors prepared in DMSO were diluted in 539 
culture media and 10% DMSO in culture media was used as negative control. After the 540 
required incubation period, trypan blue (0.5% final, Sigma) and Live/Dead Aqua 541 
(Invitrogen) were added and the cells analysed by flow cytometry; 25,000 live/single 542 
events were used to generate statistical analyses. 543 
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Confocal microscopy 544 
FACS purified DC (FSChigh MHCII+ DEC-205+ CD11c+ CD8a-) were cultured on collagen-545 
treated coverslips (Sigma) in the presence (moi = 10) or absence of labelled AdV5. The 546 
cells were fixed with 3% paraformaldehyde for 20 minutes, washed twice with PBS and 547 
permeabilized with 0.1% Triton X-100 in PBS. Anti-EEA1 polyclonal antibody raised in 548 
rabbits (1 µg/ml final concentration, Abcam, UK) was used to visualize early endosomal 549 
compartments; the tracer molecules dextran and albumin (both at 0.5 µg/ml final 550 
concentration) conjugated to AF488 were used for co-localization assays; rabbit anti-551 
FMDV was used as a negative control (final dilution of 1:750). Goat anti-rabbit-AF488 (1 552 
µg/ml, Invitrogen) was used as secondary antibody and all samples were counterstained 553 
with DAPI (100 nM, Invitrogen) following the manufacturer’s instructions. Where indicated, 554 
Phalloidin-AF488 (0.2 U/slide, Invitrogen) was used to identify actin filaments. Cells were 555 
mounted onto microscope slides using VectaShield (Vector Laboratories, UK) and 556 
observed using a 65x lens mounted on a Leica SP5 confocal microscope. The Leica LAS 557 
AF software was used to take sequential, 3D stack images in the Z-plane acquiring stacks 558 
of 80 to 120 optical sections from infected cells as optimized by the software. The number 559 
of intracellular virions, 3D images and co-localization datasets were analysed using 560 
Bitplane Imaris 6.4.2 image analysis software (Bitplane, Switzerland) with surface 561 
smoothing of 0.05 nm for nuclei (blue), 0.02 nm for AdV (red) and endosomes (green).  562 
pH-dependent fluorometry 563 
Dextran-fluorescein (Invitrogen) was used to measure intracellular pH essentially as 564 
described previously (Downey et al., 1999). Calibration of the fluorescence ratio versus pH 565 
was performed for each experiment by equilibrating the cells in isotonic K+-rich medium 566 
buffered to varying pH values (between 5.0 and 7.5) in the presence of the K+/H+ 567 
ionophore nigericin (5 mM, Sigma). Calibration curves were constructed by plotting the 568 
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extracellular pH, which was assumed to be identical to the cytosolic pH under these 569 
conditions, against the corresponding fluorescence ratio. AdV5 (moi = 100) or dextran (25 570 
µg/ml) labelled with fluorescein were added to ALDC or 293 cells cultured in triplicate in 571 
96-well plates (Costar). Real time fluorometry was measured every 30 minutes using an 572 
Infinite M200 (Tecan) and the results analysed using Magellan for Windows (Tecan).  573 
Generation of oil-in-water emulsions 574 
AdV5 recombinants expressing GFP or Ag85A were mixed with the adjuvant Montanide 575 
ISA 206V (SEPPIC, France) to form oil-in-water emulsions following the manufacturer’s 576 
instructions. Briefly, 1x109 vp in a volume of 250 µl were mixed with an equal volume of 577 
adjuvant and vigorously mixed for 2 minutes. Two negative controls were also prepared, 578 
one containing AdV5 and adjuvant but without mixing, and the other PBS mixed with ISA 579 
206V and emulsified as described above. The emulsions containing 100 vp/cell were 580 
added to 96-well U-bottomed tissue culture plates containing 1x105 ALDC in 100 µl of 581 
media and mixed by pipetting until the solution looked homogenous. In the case of the 582 
control containing AdV5 and adjuvant without mixing, the solutions were mixed only once 583 
and clear hydrophobic/hydrophilic globules observed macroscopically. The infection 584 
allowed to continue as described in the text and washed twice with PBS before analysis. 585 
Antigen presentation assays 586 
Ag85A-specific IFN-g producing lymphocytes were analysed using ELISpot assays as 587 
described previously (Guzman et al., 2012; Hope et al., 2012) utilizing purified CD4+ T 588 
cells from MHC-matched, BCG-vaccinated animals (Thom et al., 2012). 589 
Statistical analysis 590 
Calculation of descriptive statistics (geometric statistics, standard error of the means and 591 
standard deviations), two-way parametric analysis of variants (ANOVA) including multiple 592 
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comparisons, Bonferroni multiple comparison tests and graphs were generated using 593 
GraphPad Prism for Windows v6.01 (GraphPad, San Diego, CA). 594 
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FIGURE LEGENDS 846 
Figure 1. Phenotype of ALDC and expression of CAR in bovine cells. a) The phenotype of 847 
ALDC was characterized as FSChigh MHC class II+ DEC205+ CD11c+ CD8α- and 91% of 848 
these cells were CD172a+. The plot is representative of all samples analysed (n = 8 849 
animals). b) Expression of CAR and b-actin was assessed by Western blot on enriched 850 
membrane fractions from 293, bovine lung (BL) or ALDC. Blot representative of 3 different 851 
experiments. c and d) Virus overlay protein binding assay (VOPBA) was used to confirm 852 
binding of AdV5 to enriched membrane fractions from 293 and BL but not from ALDC 853 
under denaturing and non-denaturing conditions. e) Competition VOPBA using anti-CAR 854 
antibodies to block binding of AdV5 to enriched membrane fractions from 293 and BL 855 
cells. Blots representative of 5 different experiments. 856 
 857 
Figure 2. Transduction of ALDC by AdV5-GFP following removal of putative receptors 858 
from the cells’ surface. a-f) Expression of putative AdV5 receptors on ALDC 24 hrs after 859 
treatment (doted histograms) or mock treatment (solid histograms); grey-filled histograms: 860 
isotype controls. g-l) Expression of GFP in AdV5-GFP transduced untreated (solid 861 
histograms), treated (doted histograms) or mock transduced ALDC (grey-filled 862 
histograms). m and n) Expression of GFP in AdV5-GFP-transduced ALDC and 293 cells in 863 
the presence of the RGD antagonist Cyclo(Ala-Arg-Gly-Asp-3-Aminomethylbenzoyl (doted 864 
histogram) or control peptide (solid histogram); grey-filled histogram: mock transduced 865 
cells. o and p) Expression of GFP in AdV5-GFP-transduced ALDC and 293 in the 866 
presence of AdV5-hyperimmune bovine sera (doted histograms), normal bovine serum 867 
(solid histograms) or mock transduced (grey-filled histograms). Plots are representative of 868 
cells from 6 different animals analysed in duplicate. 869 
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Figure 3. AdV5 entry and trans-gene expression in ALDC is significantly different from that 870 
in CAR-expressing 293 cells. ALDC (white circles) and 293 cells (black squares) were 871 
cultured on ice (4oC) or at 37ºC with biotinylated AdV5-GFP for 90 minutes followed by 872 
washing off the inoculum. a) Biotinylated membrane-bound virus was detected by ELISA 873 
using streptavidin-HRP. b) Cells were transduced as before and cultured for 24 hrs at 874 
37ºC; expression of the trans-gene (GFP) was detected by flow cytometry. c) ALDC and 875 
293 cells were cultured at 37ºC in the presence of AdV5-GFP.  At 1 hr intervals, aliquots 876 
were washed with PBS and the cells allowed to recover overnight after which GFP 877 
expression was measured by flow cytometry. d) ALDC and 293 cells were cultured at 37ºC 878 
in the presence of AdV5-GFP and without washing; GFP expression was measured by 879 
flow cytometry at 1 hr intervals. Each point represents the mean of cells from 6 different 880 
animals tested in duplicate and error bars indicate standard error of the mean.   881 
Figure 4. Uptake of AdV in DC is blocked by inhibitors of actin-dependent endocytosis. 882 
ALDC and 293 cells were cultured with AdV5-Fluo for 1 hr at 37ºC in the presence of 883 
various endocytosis inhibitors as described in materials and methods. Extracellular 884 
fluorescein was then quenched with trypan blue and fluorescence was measured by flow 885 
cytometry. A) Representative histograms showing fluorescence after various treatments. 886 
The markers indicate percentage of fluorescein-positive cells above background. b) Bar 887 
graphs showing means and standard deviations of the percentage of fluorescein+ ALDC 888 
obtained from 6 different animals and tested in duplicate or 293 cells tested in triplicate. 889 
Asterisks indicate *=p<0.05 and **=p<0.005 compared to treatment with DMSO. 890 
Figure 5. Entry of AdV5 into ALDC. ALDC were cultured at 37ºC in the presence of 891 
AF568-labelled AdV5 (moi = 100). Cells were fixed and analysed by confocal microscopy 892 
at 3 hrs (a) 4hr (b) or 5 hrs (d) post infection. Blue: DAPI; Green: Phalloidin-AF488 (for F-893 
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actin); Red: AdV5-AF568. Representative samples of cells from 5 different animals. The 894 
scale bar represents 20 µm. 895 
 896 
Figure 6. The majority of AdV are not associated with early endosomes. ALDC were 897 
cultured with AdV5-AF568 (red) and Dextran-AF488 (green) or albumin-AF488 (green) for 898 
4 hrs and fixed. The early endosome marker (EEA1) was detected using monospecific 899 
antibodies and AF488 secondary antibodies (green) as described in Materials and 900 
Methods and the samples analysed by confocal microscopy. a) Colocalization of AdV5 and 901 
EEA1; b) AdV5 and dextran; d) AdV5 and albumin. Blue: DAPI; Yellow: co-localization. 902 
Inserts show a higher magnification of the region of interest. Arrows indicate colocalization 903 
events. Representative samples cells from 4 different animals. d) Bar graph showing mean 904 
percentage of co-localization voxels from single-slice histograms across the Z-plane from 905 
at least 10 confocal images processed from cells from 4 different animals. Error bars 906 
indicate standard error of the mean.  907 
Figure 7. Acidification of endosomes is not required for transduction of ALDC by AdV5. a) 908 
ALDC or 293 cells were incubated with AdV5-GFP for 24 hrs in the presence of various 909 
inhibitors of intracellular acidic microenvironment or with the diluents DMSO or PBS. 910 
Trans-gene expression (GFP) was measured by flow cytometry. b) ALDC were cultured at 911 
37ºC with fluorescein-labelled AdV5 or dextran for 4 hrs in the presence of normal tissue 912 
culture media or media containing 10 mM NH4Cl pH 7.5. After washing fluorescein mean 913 
fluorescence intensity (MFI) was measured by flow cytometry. c) Relative fluorescence 914 
standard curve of fluorescein-dextran at various pH. D) ALDC were cultured in the 915 
presence of fluorescein-labelled AdV5 or dextran. Relative fluorescence (RFU) was 916 
measured by real time fluorometry. Each point represents the mean of cells from 4 917 
different animals tested in duplicate and error bars indicate standard error of the mean.  918 
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Figure 8. Oil-in-water adjuvants improve AdV5 uptake by ALDC, increase and prolong 919 
recombinant antigen expression and enhance antigen presentation. AF568-labelled AdV5 920 
was mixed with PBS or an oil-in-water adjuvant, added to ALDC, cultured overnight and 921 
washed twice prior to analysis. a) Confocal microscopy was used to count the number of 922 
intracellular virions/cell 4 hrs post infection. b and c) 3D reconstructions of representative 923 
samples of ALDC infected with AdV5-568 in PBS or adjuvant respectively 4 hrs post 924 
infection. d) GFP mean fluorescence intensity (MFI) of ALDC infected with AdV5-GFP in 925 
PBS or adjuvant 24 hrs post infection. e) Frequency of GFP-expressing ALDC over time 926 
following infection with AdV5-GFP in PBS or adjuvant. f) Ag85A-specific IFN-g ELISpot 927 
using AdV5-Ag85A or AdV5-GFP in PBS or adjuvant. ALDC were infected with AdV5 928 
recombinants as described in Materials and Methods and cultured with MHC-matched 929 
CD4+ T cells from BCG-vaccinated animals. In all cases the bars indicate means of 20 930 
imaged cells from 3 different animals analysed in duplicate and error bars indicate 931 
standard error of the means. 932 
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S1.	Neutralizing	antibodies	do	not	prevent	virus	entry	into	ALDC.	AF568-labelled	AdV5	was	mixed	
with	PBS,	normal	bovine	sera	or	bovine	hyperimmune	sera	to	AdV5	and	incubated	for	60	min	after	
which	the	mix	was	added	to	ALDC	as	described	in	Materials	and	Methods	and	confocal	microscopy	
was	used	to	quantify	the	number	of	intracellular	AF568-labelled	virions.	a)	Mean	number	of	
intracellular	AF568+	particles	per	cell.	Bars	indicate	means	of	cells	from	5	different	animals	analysed	
in	duplicate	and	error	bars	indicate	standard	error	of	the	means.	b	and	d)	Three-dimensional	
reconstructions	from	confocal	micrographs	showing	ALDC	cultured	for	5	hrs	with	AdV5-AF568	
previously	incubated	with	hyperimmune	sera	(b)	or	normal	sera	(c).	Reconstructions	are	
representative	of	cells	from	5	independent	experiments.	Black	bar	indicates	5	microns.		
	
